CRVS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CRVS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Corvus Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $1.04 Mil. Corvus Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.00 Mil. Corvus Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $33.36 Mil. Corvus Pharmaceuticals's debt to equity for the quarter that ended in Mar. 2024 was 0.03.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Corvus Pharmaceuticals's Debt-to-Equity or its related term are showing as below:
During the past 10 years, the highest Debt-to-Equity Ratio of Corvus Pharmaceuticals was 0.06. The lowest was 0.02. And the median was 0.04.
The historical data trend for Corvus Pharmaceuticals's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corvus Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Debt-to-Equity | Get a 7-Day Free Trial | 0.05 | 0.03 | 0.04 | 0.05 | 0.04 |
Corvus Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Debt-to-Equity | Get a 7-Day Free Trial | 0.05 | 0.04 | 0.04 | 0.04 | 0.03 |
For the Biotechnology subindustry, Corvus Pharmaceuticals's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Corvus Pharmaceuticals's Debt-to-Equity falls into.
Debt to Equity measures the financial leverage a company has.
Corvus Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (1.374 | + | 0) | / | 38.684 | |
= | 0.04 |
Corvus Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (1.04 | + | 0) | / | 33.364 | |
= | 0.03 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corvus Pharmaceuticals (NAS:CRVS) Debt-to-Equity Explanation
In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.
Be Aware
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thank you for viewing the detailed overview of Corvus Pharmaceuticals's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Linda S Grais | director | 86 ALEJANDRA AVE, ATHERTON CA 94027 |
William Benton Jones | officer: See Remarks | 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
Leiv Lea | officer: Chief Financial Officer | PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521 |
Miller Richard A Md | director, officer: President and CEO | PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521 |
Ecor1 Capital, Llc | 10 percent owner | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Peter A. Thompson | director, 10 percent owner | C/O ANTHERA PHARMACEUTICALS, INC., 25801 INDUSTRIAL BOULEVARD, SUITE B, HAYWARD CA 94545 |
Orbimed Advisors Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Edith P. Mitchell | director | 1640 MARENGO ST., LOS ANGELES CA 90033 |
Novo Holdings A/s | 10 percent owner | TUBORG HAVNEVEJ 19, HELLERUP G7 2900 |
Mehrdad Mobasher | officer: Chief Medical Officer | 863 MITTEN ROAD, BURLINGAME CA 94010 |
Adams Street Partners Llc | 10 percent owner | ONE NORTH WACKER DRIVE, STE 2700, CHICAGO IL 60606-2807 |
Terry P Gould | director, 10 percent owner | C/O ONCOMED PHARMACEUTICALS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063 |
Joseph J Buggy | officer: EVP Discovery Research | CORVUS PHARMACEUTICALS, INC., 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
Daniel W. Hunt | officer: SVP, Chief Business Officer | 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
Erik J. Verner | officer: V.P., Chemistry Research | 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
From GuruFocus
By Value_Insider Value_Insider • 11-14-2022
By sperokesalga sperokesalga • 03-21-2023
By sperokesalga sperokesalga • 05-31-2023
By GuruFocusNews GuruFocusNews • 06-29-2022
By GuruFocusNews GuruFocusNews • 07-05-2022
By Value_Insider Value_Insider • 10-25-2022
By PurpleRose PurpleRose • 08-08-2022
By sperokesalga sperokesalga • 02-21-2023
By Marketwired • 08-08-2023
By sperokesalga sperokesalga • 06-15-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.